Bradley J. Monk, MD, FACS, FACOG

Christian Marth, MD, PhD, reviews the adverse effects of pembrolizumab and lenvatinib in the treatment of endometrial cancer, as well as the patient experience with these treatments.

Bradley J. Monk, MD, FACS, FACOG, and Christian Marth, MD, PhD, share treatment approaches to patients with endometrial cancer with a low response rate to chemotherapy, highlighting a biomarker-based approach.

Experts discuss the possibility to avoid use of chemotherapy by using immunotherapy.

Christian Marth, MD, PhD, and Bradley J. Monk, MD, FACS, FACOG, discuss data from the NRG GY018 and RUBY trials regarding the use of immunotherapies for the treatment of endometrial cancer.

Bradley J. Monk, MD, FACS, FACOG, reviews the available chemotherapy options for treating advanced and recurrent endometrial cancer, as well as compares notes with Christian Marth, MD, PhD, on his clinical experience.

Christian Marth, MD, PhD, discusses the prevalence of endometrial cancer, as well as the steps that lead to diagnosis.

The panel closes their discussion by highlighting their favorite news or update from recent conferences, including ESMO 2022.

Dr Shannon Westin explains the data on treatment of rare tumors in ovarian cancer and why biomarker testing is essential.

A key opinion leader reviews data on novel investigational agents for recurrent ovarian cancer.

Drs Coleman and Westin continue the discussion of antibody-drug conjugates for treatment of ovarian cancer.

Dr Michael Birrer highlights updated data on antibody-drug conjugates in ovarian cancer treatment.

Dr Shannon Westin shares if and when she could justify withholding a PARP inhibitor from a patient with HRD-positive ovarian cancer.

Experts discuss the best approach to treating patients with ovarian cancer who are resistant to PARP inhibitors.

A look at the maintenance treatment strategies for advanced or metastatic ovarian cancer.

Michael J. Birrer, MD, PhD, explains the reasoning for combining PARP inhibitors with immunotherapy in ovarian cancer treatment, highlighting ongoing trials.

Robert L. Coleman, MD, FACOG, FACS, describes data updates from the PRIMA trial investigating PARP inhibition in HRD-negative ovarian cancer populations.

Dr Michael Birrer reviews data from the PAOLA-1 trial investigating bevacizumab combination therapy for frontline maintenance therapy in advanced ovarian cancer.

Bradley J. Monk, MD, FACOG, FACS, generates a discussion on the use of PARP inhibitors in ovarian cancer treatment.

Shannon N. Westin, MD, MPH, FACOG, explains the study design and outcomes of the SOLO-3 trial.

Dr Robert Coleman reviews data from the ARIEL-4 trial on rucaparib in recurrent ovarian cancer, sparking a discussion on PARP inhibitor use.

Bradley J. Monk, MD, FACS, FACOG, discusses existing unmet needs in the treatment of patients with recurrent ovarian cancer.